Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-05-15 19:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 496.4 KB | ||
| 2014-05-12 18:30 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 378.5 KB | ||
| 2014-05-12 18:30 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 368.8 KB | ||
| 2014-04-28 21:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 501.5 KB | ||
| 2014-04-28 21:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 525.3 KB | ||
| 2014-04-22 18:35 |
Communicated under the obligation to provide permanent information / Communicat…
|
English | 77.4 KB | ||
| 2014-04-22 18:35 |
Communiqués au titre de l'obligation d'information permanente / Communiqué sur …
|
French | 82.7 KB | ||
| 2014-04-22 11:13 |
Communiqués de mise à disposition de documents / Modalités de mise à dispositio…
|
French | 13.2 KB | ||
| 2014-03-26 17:40 |
Communiqués au titre de l'obligation d'information permanente / Communiqué sur …
|
French | 693.1 KB | ||
| 2014-03-26 17:40 |
Communicated under the obligation to provide permanent information / Communicat…
|
English | 695.7 KB | ||
| 2014-03-26 08:45 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 554.4 KB | ||
| 2014-03-26 08:45 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 563.1 KB | ||
| 2014-03-25 16:15 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 368.2 KB | ||
| 2014-03-25 16:15 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 421.5 KB | ||
| 2014-03-25 07:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 538.4 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
